Legion Healthcare Partners is pleased to announce the addition of James Welsh, MD to its Scientific Advisory Board. Dr. Welsh is an Associate Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center.
| HOUSTON, March 18, 2020 /PRNewswire/ -- Legion Healthcare Partners is pleased to announce the addition of James Welsh, MD to its Scientific Advisory Board. Dr. Welsh is an Associate Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center. Dr. Welsh is focused on enhancing the effects of immunotherapy through its rational combination with radiation. Dr. Welsh oversees the immunotherapy lab while also treating patients which provides him with unique clinical insight that comes from seeing firsthand how best to combine immunotherapies with radiation. Dr. Welsh’s expertise in immuno-RT programmatic development expands Legion’s ability to provide a comprehensive level of knowledge in this important field of particle therapy with their partners around the world.
“The addition of Dr. Welsh to our Advisory Board is paramount to our mission. He provides expertise in immunotherapy that will benefit our clinical partners. In addition, it provides a necessary diversity between patient treatment and research. Jim is on the forefront of investigating and proving the benefits of the immunotherapy in combination with radiation and in particular, with proton therapy. As a physician scientist, he is wholly dedicated to cancer care, radiation oncology and our plight to end this disease. We are honored to have him as a scientific member of our Advisory Board,” says John Styles, Chairman and CEO of Legion Healthcare Partners. Dr. Welsh started his oncology career in the Department of Molecular Oncology at Genentech Inc. While at Genentech he helped to discover and clone the Wnt-Induced secreted proteins (WISP) family of oncogenes. He later attended Dartmouth Medical School and completed his residency in radiation oncology at the University of Arizona. There Dr. Welsh helped develop a novel drug targeting c-Met kinase (MP-470. Currently, Dr. Welsh serves as the director of the immuno-radiation program at MD Anderson. One of the goals of the program is to prime T cells through an “in-situ” vaccine developed from irradiated tumor tissue, thereby allowing for radiation to operate as a systemic therapy. Dr. Welsh’s research includes over 5,220 Citations, 108 Articles and 6 Chapters. About Legion Healthcare Partners (legionhp.com) Legion Healthcare Partners is a group of healthcare executives, clinical advisors and domain experts that provide financing, ownership, development, management services and certified educational programs for radiation oncology with an emphasis on proton therapy. Legion provides a value-based approach powered by proprietary technology solutions to help manage healthcare providers financial and operational efficiency. Legion Healthcare Partners is based in Houston, Texas. For more information, visit www.legionhp.com or email info@legionhp.com.
SOURCE Legion Healthcare Partners |
View original content to download multimedia:
